Primary Age-Related Tauopathy (PART) is a neurodegenerative condition characterized by the presence of neurofibrillary tangles (NFTs) in the absence of significant amyloid-beta (Aβ) pathology. In this model, in the absence of comorbid Aβ, alpha-synuclein (a-SN), or TDP-43 pathologies, tau/NFT pathology develops during aging in all humans, evolving in a brainstem-toward-cortex direction following the Braak staging scheme.
Type: disease_model
Confidence Level: established
Diseases Associated:
- Primary Age-Related Tauopathy (PART)
- Alzheimer Disease (AD)
- Aging-related tauopathy
The locus coeruleus (LC) is one of the earliest sites of tau pathology:
- Earliest involvement - NFTs appear in the LC before other brain regions
- Noradrenergic neurons - These neurons are particularly vulnerable
- Noradrenergic modulation - Loss affects attention, arousal, and stress response
- Vulnerability factors - High metabolic activity, iron accumulation
Tau is a microtubule-associated protein:
- Normal function - Stabilizes microtubules in axons
- Hyperphosphorylation - Pathological tau is hyperphosphorylated
- Aggregation - Forms paired helical filaments (PHFs) and NFTs
- Spread - Prion-like propagation between neurons
NFTs are intracellular aggregates of hyperphosphorylated tau:
- Composition - Paired helical filaments of phosphorylated tau
- Neuronal loss - NFTs correlate with neuronal death
- Braak staging - NFT distribution defines disease progression
- Cognitive correlation - NFT burden correlates with cognitive decline
The Braak staging system describes NFT spread:
- Stage I/II - Locus coeruleus and adjacent brainstem
- Stage III/IV - Transentorhinal and entorhinal cortex
- Stage V/VI - Isocortex (primary sensory and motor areas)
The medial temporal lobes are critically involved:
- Entorhinal cortex - Gateway for hippocampal-cortical connections
- Hippocampus - Memory formation and consolidation
- Amygdala - Emotional processing and memory
- Early vulnerability - These regions show early NFT involvement
Tau pathology in PART follows a characteristic progression:
- Locus coeruleus - Earliest and most severely affected
- Dorsal raphe nucleus - Serotonergic system involvement
- Transentorhinal cortex - Entry point to the limbic system
- Entorhinal cortex - Grid cell dysfunction
- Hippocampus - Memory impairment
- Isocortex - Global cognitive decline
PART is distinguished by its age-related onset:
- Prevalence - Found in 70-100% of elderly individuals
- Age of onset - Typically after age 60
- Clinical course - Often asymptomatic or mild cognitive impairment
- Progression - Slow progression over decades
Key distinguishing features:
| Feature |
PART |
AD |
| Aβ pathology |
Absent/minimal |
Present |
| NFT distribution |
Brainstem-first |
Limbic-first |
| Age of onset |
Later |
Earlier |
| Cognitive decline |
Mild |
Progressive |
- CBD - Corticobasal degeneration has asymmetric onset
- PSP - Progressive supranuclear palsy has vertical gaze palsy
- FTD - Frontotemporal dementia has frontotemporal atrophy
PART patients typically show:
- Memory impairment - Episodic memory deficits
- Executive dysfunction - Planning and decision-making issues
- Preserved daily function - Often remain independent
- Slow progression - Gradual decline over years
CSF and imaging biomarkers:
- CSF tau - Elevated total tau, normal Aβ
- PET imaging - Tau PET shows medial temporal lobe signal
- MRI - Hippocampal atrophy
Multiple studies support this disease model:
- Neuropathological studies - NFT distribution in aging brains
- Biomarker studies - CSF and PET imaging findings
- Genetic studies - APOE status in PART vs. AD
- Longitudinal studies - Progression patterns in aging cohorts
- NFT burden in the absence of Aβ plaques is common in the elderly
- The locus coeruleus shows earliest and most severe involvement
- Cognitive impairment correlates with NFT burden regardless of Aβ status
Potential interventions for PART:
- Anti-tau therapies - Immunotherapies targeting tau
- Tau aggregation inhibitors - Small molecules preventing NFT formation
- Neuroprotective agents - Protecting against tau-induced toxicity
- Symptomatic treatments - Cholinesterase inhibitors for cognitive symptoms
- Early detection is difficult
- No approved disease-modifying therapies
- Biomarkers need validation
- Clinical trials require careful patient selection
Key approaches to studying PART:
- Neuropathology - Postmortem brain analysis
- Biomarkers - CSF and PET imaging
- Genetics - APOE and other genetic factors
- Longitudinal studies - Cohort studies of aging
- Animal models - Transgenic tau models
- Primary Age-Related Tauopathy (PART) (2019)
- Tau pathology spreading in the brain (2018)
- Locus coeruleus in aging and neurodegeneration (2020)
- SEA-AD: Seattle-Alzheimer's Disease Brain Cell Atlas
- The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases